<DOC>
	<DOCNO>NCT01218113</DOCNO>
	<brief_summary>This study design determine whether administration GSK Biologicals HIV vaccine 732462 lead reduction viral load , impact course human immunodeficiency virus type 1 ( HIV-1 ) infection . In HIV-1 infected person yet start antiretroviral therapy ( ART ) , vaccine would potentially lead delay initiation treatment .</brief_summary>
	<brief_title>Efficacy Safety GSK Biologicals HIV Vaccine Antiretroviral Therapy ( ART ) -naïve HIV-1 Infected Persons</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects investigator believe comply requirement protocol . Written inform consent obtain subject prior study procedure . A male female include 1855 year time first vaccination . Known HIV1 infect care HIV physician minimum 6 month . However , subject initially present clinical diagnosis primary HIV infection need diagnose care least 12 month . ARTnaïve . Individuals must never receive ART HIV diagnosis , include lamivudine use chronic hepatitis B infection , exception shortterm ART prevention mothertochild transmission ( PMTCT ) least 12 month prior enrollment . Commencement ART expect , base current assessment , within next 12 month . Viral load level 2,00080,000 copies/mL screening . CD4 count &gt; = 500 cell per mm3 screening . If subject female , must nonchildbearing potential , i.e . current tubal ligation , hysterectomy , ovariectomy postmenopausal . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test screening , agree continue adequate contraception entire study period . The following criterion check time screen vaccination . If ANY exclusion criterion applies , subject must include study : Infection HIV2 . This include patient dual infection HIV1/HIV2 . Had Acquired Immune Deficiency Syndrome ( AIDS ) define clinical illness . Use investigational nonregistered product within 4 week precede first dose study vaccine/placebo , plan use investigational nonregistered product study vaccine study period . Drug therapy immunomodulators steroid within 12 week precede first dose study vaccine/placebo plan administration study period . Acute use steroid 4 week precede first dose treatment hypersensitivity reaction exclusion criterion . Inhaled topical steroid allow . Administration immunoglobulins and/ blood product within 12 week precede first dose study vaccine/placebo plan administration study period . Planned administration vaccine foreseen study protocol period start 2 week first dose study vaccine/placebo end Visit 3 ( Week 6 ) ( blood sampling ) , period start 2 week prior Visit 5 ( Week 28 ) end Visit 6 ( Week 30 ) ( blood sample ) period start 2 week prior Visit 8 ( Week 48 ) end Visit 8 ( Week 48 ) ( blood sampling ) , exception nonadjuvanted influenza vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Any previous vaccination immunotherapy HIV . A family history hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Acute chronic infective hepatitis . Acute chronic , clinically relevant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination and/or medical history screening . Grade 3 grade 4 laboratory abnormality , define Division od AIDS ( DAIDS ) grade table , screen Pregnant lactate female . Any condition , opinion investigator , could compromise subject 's safety adherence study protocol . History medically confirm autoimmune disease . History malignancy , squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . Unstable asthma Food wine induce asthma . Known sensitivity sulfites aspirin . Known sensitivity aminoglycoside antibiotic . Contraindication intramuscular injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Human Immunodeficiency Virus ( HIV ) -1</keyword>
	<keyword>safety</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>reactogenicity</keyword>
	<keyword>HIV infection</keyword>
</DOC>